Literature DB >> 12634991

[New immunosuppressive agents for treating psoriasis].

S Ortiz-Urda1, K Rappersberger.   

Abstract

Accumulative evidence suggests that psoriasis may be a genetically determined immunologenic inflammatory disorder based on an ongoing autoreactive Th-1 response. Various cytokines (e.g. IL-2, interferon-gamma etc.) are released and exert proliferative signals on to keratinocytes, which start proliferation that finally results in an incomplete differentiation. During this pathobiological process keratinocytes themselves express receptors that make them sensitive for growth inducing stimulation and also start the production of a set of cytokines that contribute to and maintain inflammation. Immunosuppressive agents, mostly by affecting T-cells may interfere with or even disrupt by rather unspecific mechanisms, this complex process of mutual stimulation of leucocytes and keratinocytes. In this manuscript we show mode of action, efficacy and side effects of Methotrexate, Ciclosporin A, Tacrolimus and Pimecrolimus, and discuss therapeutic options with mycophenolate mofetil and fumaric acid esters.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634991     DOI: 10.1007/s00105-003-0499-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  31 in total

1.  Treatment of severe psoriasis and psoriatic arthritis with leflunomide.

Authors:  K Reich; K M Hummel; I Beckmann; R Mössner; C Neumann
Journal:  Br J Dermatol       Date:  2002-02       Impact factor: 9.302

2.  Topical application of mycophenolate mofetil in plaque-type psoriasis.

Authors:  J Wohlrab; K Jahn; M Plaetzer; R Neubert; W C Marsch
Journal:  Br J Dermatol       Date:  2001-06       Impact factor: 9.302

Review 3.  Methotrexate in psoriasis: consensus conference.

Authors:  H H Roenigk; R Auerbach; H Maibach; G Weinstein; M Lebwohl
Journal:  J Am Acad Dermatol       Date:  1998-03       Impact factor: 11.527

4.  Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference.

Authors:  U Mrowietz; E Christophers; P Altmeyer
Journal:  Br J Dermatol       Date:  1999-09       Impact factor: 9.302

5.  [Immunosuppressive macrolides and their use in dermatology].

Authors:  E C Bornhövd; E Schuller; T Bieber; A Wollenberg
Journal:  Hautarzt       Date:  2000-09       Impact factor: 0.751

Review 6.  Consensus conference on cyclosporin A for psoriasis February 1992.

Authors:  M J Mihatsch; K Wolff
Journal:  Br J Dermatol       Date:  1992-06       Impact factor: 9.302

7.  Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection.

Authors:  S M Stepkowski; L Tian; K L Napoli; R Ghobrial; M E Wang; T C Chou; B D Kahan
Journal:  Clin Exp Immunol       Date:  1997-04       Impact factor: 4.330

8.  Chemokine production by G protein-coupled receptor activation in a human mast cell line: roles of extracellular signal-regulated kinase and NFAT.

Authors:  H Ali; J Ahamed; C Hernandez-Munain; J L Baron; M S Krangel; D D Patel
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

9.  Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo.

Authors:  Holger Hackstein; Timucin Taner; Alan F Zahorchak; Adrian E Morelli; Alison J Logar; Andre Gessner; Angus W Thomson
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

10.  Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model.

Authors:  M Erdogan; J R Wright; V C McAlister
Journal:  Br J Dermatol       Date:  2002-06       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.